Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
Date:12/10/2010

tatements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, and mechanism of action of APD811; the potential of APD811 and orally bioavailable prostacyclin receptor agonists in general, including with regard to improving treatment; the protocol, design, scope, enrollment, potential results and other aspects of the Phase 1 clinical trial for APD811; Arena's earlier-stage compounds and related value and potential; Arena's focus on the approval of lorcaserin; the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's aim, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: there was a small safety margin from the no observed adverse effect level to significant adverse events in preclinical studies of APD811, and APD811 could have an unacceptable safety and efficacy profile in humans; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval of the lorcaserin NDA; unexpected new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timi
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
3. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
7. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
8. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
9. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  RESMED INC. (NYSE: RMD ... and fiscal year ended June 30, 2014 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
(Date:7/10/2014)...  BC Technical, the largest nationwide, non-OEM provider of ... a leading provider of Siemens Nuclear Medicine and Molecular ... BC Technical as the authorized provider of service and ... BC Technical announced today that the two companies have ... the service and systems provider for MiE,s camera systems. ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Oct. 17, 2011 Archimedes Pharma Ltd., and its ... (fentanyl) nasal spray is now available by prescription in ... breakthrough pain in cancer patients 18 years of age ... tolerant to opioid therapy for their underlying persistent cancer ...
... Calif., Oct. 17, 2011 Abaxis, Inc. (NasdaqGS: ABAX), a ... a conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on Tuesday, ... the second quarter of fiscal year 2012 after the market ...
Cached Medicine Technology:Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Most professional football ... return to the game, a new study finds. ... but their rate of return after surgery to fix ... The new study included 60 players who had ... this procedure successfully returned to play, defined as playing ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... the hot flashes that often accompany menopause, new research suggests. ... percent of menopausal women, said Dr. Taraneh Shirazian, an assistant ... Icahn School of Medicine at Mount Sinai Hospital in New ... 10 hot flashes a day, and she added that hot ...
(Date:7/10/2014)... By Dennis Thompson ... -- About six out of 10 adults make use of ... to order in restaurants, according to a new U.S. study. ... study,s lead author, Seung Hee Lee-Kwan, an epidemiologist with the ... of women surveyed said they used menu labeling to help ...
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Knopp Neurosciences Inc. ("Knopp"),announced that Cheryl Fossum Graham, ... president of regulatory and development strategy. (Logo: ... to Knopp 28 years of experience in public ... Food,and Drug Administration and responsibility for global regulatory ...
... ALOKA is announcing today 3 new models of,ProSound Systems ... on,Ultrasound in Obstetrics and Gynecology, 7th to 11th of ... a powerful, friendly and compact,premium ultrasound system, the ProSound ... system worldwide and the ProSound 6,is a new premium ...
... Nancy Pelosi,released the following statement today in recognition ... presented the National Breast,Cancer Coalition,s "Wo(men) Who Get ... "National Breast Cancer Awareness Month is a ... ourselves to advancing prevention, improving,treatments, and funding research ...
... 29, over 850,people in 60 cities across the country ... the Crossfit Fight Gone Bad Challenge to,raise money for ... Cancer,Foundation. Over 4,000 donors supported the cause by contributing ... funds grant from Safeway, the,event raised over $546,000 in ...
... advance in understanding the genetic processes that give flowers, ... lead to a range of benefits, including better understanding ... natural food colourings. The research is highlighted in the ... Sciences Research Council (BBSRC). , The scientists, at the ...
... support services in Los ... Angeles, ... in association with the Will and Jada Smith,Family Foundation hosted the First ... Rey Theatre in Los,Angeles. Actress Jada Pinkett Smith headlined a group of ...
Cached Medicine News:Health News:Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 2Health News:Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 3Health News:Aloka to Unveil New 'ProSound' Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy 2Health News:Aloka to Unveil New 'ProSound' Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy 3Health News:Crossfit Workout Challenge Raises Over $500,000 in Four Hours for Athletes for a Cure 2Health News:New research into plant colors sheds light on antioxidants 2Health News:Stars Shine on 'Butterflies Over Hollywood' for Lupus Foundation of America 2
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
... has been designed to enhance fixation in ... hole configurations. The objective of the product ... primary modes: Tilt, migration and rotation. The ... initial and long-term fixation. The porous coating ...
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: